Literature DB >> 15090459

Genomic DNA-chip hybridization in t(11;14)-positive mantle cell lymphomas shows a high frequency of aberrations and allows a refined characterization of consensus regions.

Holger Kohlhammer1, Carsten Schwaenen, Swen Wessendorf, Karlheinz Holzmann, Hans A Kestler, Dirk Kienle, Thomas F E Barth, Peter Möller, German Ott, Jörg Kalla, Bernhard Radlwimmer, Armin Pscherer, Stephan Stilgenbauer, Hartmut Döhner, Peter Lichter, Martin Bentz.   

Abstract

Tumor samples of 53 patients with t(11;14)-positive mantle cell lymphomas (MCLs) were analyzed by matrix-based comparative genomic hybridization (matrix-CGH) using a dedicated DNA array. In 49 cases, genomic aberrations were identified. In comparison to chromosomal CGH, a 50% higher number of aberrations was found and the high specificity of matrix-CGH was demonstrated by fluorescence in situ hybridization (FISH) analyses. The 11q gains and 13q34 deletions, which have not been described as frequent genomic aberrations in MCL, were identified by matrix-CGH in 15 and 26 cases, respectively. For several genomic aberrations, novel consensus regions were defined: 8p21 (size of the consensus region, 2.4 megabase pairs [Mbp]; candidate genes: TNFRSF10B, TNFRSF10C, TNFRSF10D); 10p13 (2.7 Mbp; BMI1); 11q13 (1.4 Mbp; RELA); 11q13 (5.2 Mbp; CCND1); 13q14 (0.4 Mbp; RFP2, BCMSUN) and 13q34 (6.9 Mbp). In univariate analyses correlating genomic aberrations and clinical course, 8p- and 13q14- deletions were associated with an inferior overall survival. These data provide a basis for further studies focusing on the identification of pathogenetically or clinically relevant genes in MCL.

Entities:  

Mesh:

Year:  2004        PMID: 15090459     DOI: 10.1182/blood-2003-12-4175

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  13 in total

Review 1.  Mantle cell lymphoma: evolving novel options.

Authors:  Andre Goy
Journal:  Curr Oncol Rep       Date:  2007-09       Impact factor: 5.075

2.  Parallel gene expression profiling of mantle cell lymphoma - how do we transform 'omics data into clinical practice.

Authors:  Ek Sara; Carl Ak Borrebaeck
Journal:  Curr Genomics       Date:  2007-05       Impact factor: 2.236

Review 3.  Molecular cytogenetics in haematological malignancy: current technology and future prospects.

Authors:  Lyndal Kearney; Sharon W Horsley
Journal:  Chromosoma       Date:  2005-10-15       Impact factor: 4.316

4.  Pathway discovery in mantle cell lymphoma by integrated analysis of high-resolution gene expression and copy number profiling.

Authors:  Elena M Hartmann; Elias Campo; George Wright; Georg Lenz; Itziar Salaverria; Pedro Jares; Wenming Xiao; Rita M Braziel; Lisa M Rimsza; Wing-Chung Chan; Dennis D Weisenburger; Jan Delabie; Elaine S Jaffe; Randy D Gascoyne; Sandeep S Dave; Hans-Konrad Mueller-Hermelink; Louis M Staudt; German Ott; Sílvia Beà; Andreas Rosenwald
Journal:  Blood       Date:  2010-04-26       Impact factor: 22.113

5.  Specific secondary genetic alterations in mantle cell lymphoma provide prognostic information independent of the gene expression-based proliferation signature.

Authors:  Itziar Salaverria; Andreas Zettl; Sílvia Beà; Victor Moreno; Joan Valls; Elena Hartmann; German Ott; George Wright; Armando Lopez-Guillermo; Wing C Chan; Dennis D Weisenburger; Randy D Gascoyne; Thomas M Grogan; Jan Delabie; Elaine S Jaffe; Emili Montserrat; Hans-Konrad Muller-Hermelink; Louis M Staudt; Andreas Rosenwald; Elias Campo
Journal:  J Clin Oncol       Date:  2007-02-12       Impact factor: 44.544

6.  Uniparental disomies, homozygous deletions, amplifications, and target genes in mantle cell lymphoma revealed by integrative high-resolution whole-genome profiling.

Authors:  Sílvia Beà; Itziar Salaverria; Lluís Armengol; Magda Pinyol; Verónica Fernández; Elena M Hartmann; Pedro Jares; Virginia Amador; Luís Hernández; Alba Navarro; German Ott; Andreas Rosenwald; Xavier Estivill; Elias Campo
Journal:  Blood       Date:  2008-11-04       Impact factor: 22.113

7.  Genomic deletion and promoter methylation status of Hypermethylated in Cancer 1 (HIC1) in mantle cell lymphoma.

Authors:  Heike Stöcklein; Grit Hutter; Jörg Kalla; Elena Hartmann; Yvonne Zimmermann; Tiemo Katzenberger; Patrick Adam; Ellen Leich; Sylvia Höller; Hans Konrad Müller-Hermelink; Andreas Rosenwald; German Ott; Martin Dreyling
Journal:  J Hematop       Date:  2008-07-05       Impact factor: 0.196

8.  Identified hidden genomic changes in mantle cell lymphoma using high-resolution single nucleotide polymorphism genomic array.

Authors:  Norihiko Kawamata; Seishi Ogawa; Saskia Gueller; Samuel H Ross; Thien Huynh; John Chen; Andrew Chang; Shayan Nabavi-Nouis; Nairi Megrabian; Reiner Siebert; Jose A Martinez-Climent; H Phillip Koeffler
Journal:  Exp Hematol       Date:  2009-05-27       Impact factor: 3.084

9.  TRIM13 (RFP2) downregulation decreases tumour cell growth in multiple myeloma through inhibition of NF Kappa B pathway and proteasome activity.

Authors:  Moshe E Gatt; Kohichi Takada; Mala Mani; Mikael Lerner; Marjorie Pick; Teru Hideshima; Daniel E Carrasco; Alexei Protopopov; Elena Ivanova; Olle Sangfelt; Dan Grandér; Bart Barlogie; John D Shaughnessy; Kenneth C Anderson; Daniel R Carrasco
Journal:  Br J Haematol       Date:  2013-05-07       Impact factor: 6.998

10.  Defective DROSHA processing contributes to downregulation of MiR-15/-16 in chronic lymphocytic leukemia.

Authors:  D Allegra; V Bilan; A Garding; H Döhner; S Stilgenbauer; F Kuchenbauer; D Mertens; M Zucknick
Journal:  Leukemia       Date:  2013-08-26       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.